A. Manikhas

发表

[Results of a prospective randomized investigation [Russia (St.Petersburg)/WHO] to evaluate the significance of self-examination for the early detection of breast cancer].

V. Semiglazov, A. Manikhas, V. Moiseenko, 2003, Voprosy onkologii.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Saeed Sadeghi, Allison Florance, H. Gómez, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Tibolone on Breast Cancer Cell Proliferation in Postmenopausal ER+ Patients: Results from STEM Trial

J. Foidart, M. Dowsett, A. Manikhas, 2007, Clinical Cancer Research.

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.

F. Esteva, A. Manikhas, J. Stebbing, 2017, The Lancet. Oncology.

A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer.

G. MacBeath, P. Goss, V. Semiglazov, 2014 .

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

H. Gómez, K. Blackwell, A. Manikhas, 2012, Breast Cancer Research and Treatment.

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Bing-he Xu, J. Sparano, A. Manikhas, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

M. Campone, A. Manikhas, L. Dirix, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.

R. Kreienberg, W. Jonat, N. Harbeck, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

H. Rugo, A. Manikhas, I. Bondarenko, 2021, Breast Cancer Research and Treatment.

Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.

Andreas Schneeweiss, Peter Lichter, Christof Sohn, 2007, Clinical breast cancer.

Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.

H. Gómez, V. Valero, L. Bosserman, 2012, Clinical breast cancer.

Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.

T. Whelan, D. Huntsman, W. Parulekar, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer

A. Manikhas, P. Fumoleau, A. Lundberg, 2008 .

A phase II study of pemetrexed plus carboplatin as first-line therapy of patients with locally advanced (LA) or metastatic breast cancer (MBC): Preliminary results

K. Krejcy, A. Manikhas, A. Garin, 2005 .

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

J. Baselga, M. Climent, W. Eiermann, 2010, The Lancet.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

R. Greil, J. Baselga, H. Lane, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

J. Baselga, V. Semiglazov, A. Manikhas, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER 2-positive metastatic breast cancer

J. Baselga, V. Semiglazov, A. Manikhas, 2014 .

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

H. Rugo, A. Manikhas, I. Bondarenko, 2021, Breast.

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer: A Randomized Clinical Trial

H. Rugo, A. Manikhas, I. Bondarenko, 2017, JAMA.

a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer

M. Buyse, K. Gelmon, J. Mackey, 2014 .

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

T. Whelan, S. Aparicio, D. Huntsman, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

S. Margolin, M. Desilvio, V. Semiglazov, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

K. Krejcy, A. Manikhas, A. Garin, 2008, Breast Cancer Research and Treatment.

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

J. Baselga, W. Eiermann, A. Lluch, 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase

A. Manikhas, V. Srimuninnimit, M. Matrosova, 2014, Breast cancer.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

C. Hudis, J. Baselga, V. Semiglazov, 2014 .

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

M. Ellis, J. Robertson, A. Manikhas, 2016, The Lancet.

FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer

M. Ellis, J. Robertson, A. Manikhas, 2016 .

Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane

P. Fasching, Sung-Bae Kim, M. Piccart, 2021 .

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer

M. Desilvio, A. Manikhas, S. Tjulandin, 2010, Oncology.

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study

A. Manikhas, X. Pivot, K. Jung, 2022, Breast.

A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer

K. Krejcy, A. Manikhas, I. Láng, 2012 .

P4-17-03: Incidence Rate of Asymptomatic Brain Metastases in Patients with HER2+ Metastatic Breast Cancer Screened for EGF111438/CEREBEL Study.

A. Manikhas, X. Pivot, R. Coleman, 2011 .

Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer

F. Esteva, A. Manikhas, J. Stebbing, 2018, Expert review of anticancer therapy.

Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial

A. Manikhas, J. Stebbing, V. Moiseyenko, 2023, BioDrugs.

HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin

H. Rugo, A. Manikhas, I. Bondarenko, 2017 .

Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial

A. Manikhas, J. Stebbing, A. Eniu, 2021, Breast Cancer Research and Treatment.

[Interim results of a prospective randomized study of self-examination for early detection of breast cancer (Russia/St.Petersburg/WHO)].

V. Semiglazov, A. Manikhas, V. Moiseenko, 1999, Voprosy onkologii.

A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data.

A. Schneeweiss, T. Bauknecht, A. Ruíz, 2012 .

Abstract PD1-11: nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2- advanced breast cancer

A. Manikhas, J. Cortes, V. Diéras, 2019, Poster Discussion Abstracts.

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.

L. Zelek, A. Ballestrero, L. Fallowfield, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC).

C. Hudis, J. Baselga, V. Semiglazov, 2013 .

Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).

T. Whelan, S. Aparicio, K. Gelmon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.

A. Manikhas, G. Konecny, V. Semiglazov, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.